## Accelerating In Vivo CAR-T Development: Unleashing the Power of Single Nanoparticle Characterization
**Broadcast Date:**
**Thursday, July 24, 2025**
**Time:** 8:00 am PT, 11:00 am ET, 17:00 CEST
—
### The Challenge of CAR-T Adoption
The landscape of Chimeric Antigen Receptor (CAR) T cell therapies is shifting. Despite their tremendous potential, **broad clinical adoption has faced significant hurdles**—primarily due to the **complexity, cost, and toxicity** associated with traditional **ex vivo** manufacturing. These challenges are driving researchers toward **in vivo CAR engineering** with innovative technologies, such as **lipid nanoparticles (LNPs)**.
#### Why Shift to In Vivo?
Leveraging **in vivo** methodologies holds the promise of simplifying the manufacturing process while potentially reducing costs. However, the journey is not without obstacles. The accumulation of LNPs in the **liver and spleen** often leads to mediocre transfection rates, which hinders effective targeting.
### Innovative Solutions: Targeting with Precision
**One promising solution lies in conjugating targeting proteins or antibodies to the surface of LNPs.** This development aims to improve specificity and enhance targeting capabilities. However, **quality control** remains critical. This is where **NanoFCM’s single-molecule NanoAnalyzer** technology shines, turning intricate detection and characterization into a seamless, routine task.
### Join Our Webinar for In-Depth Insights
In an upcoming session hosted by **GEN**, expert **Joseph Brealey** will explore cutting-edge strategies to bolster **quality control** in **in vivo CAR T therapies**. This is an opportunity to delve deeply into:
– How NanoFCM’s **single-molecule NanoAnalyzer** can **size and count LNPs label-free**.
– The role of this technology in **detecting mRNA loading ratios, encapsulated mRNA**, and **surface-bound ligands/antibodies**.
#### Key Takeaways: What You’ll Learn
During this engaging session, you will discover:
– The significance of **mRNA copy number per particle**, which can crucially impact overall effectiveness.
– How **encapsulation efficiency** is a game changer for in vivo application.
– The impact of **antibody/ligand decoration** on conversion efficiency for CAR T development.
**Don’t miss the chance to gain insights that could redefine your approach to CAR T therapies**!
### Engage with Experts During the Live Q&A
A dynamic **live Q&A** session will follow the presentations, providing you with the opportunity to engage directly with our expert panelist. Bring your questions and get ready for a compelling discussion!
### Produced with Support From
[NanoFCM](https://www.nanofcm.com/) is committed to advancing nanoparticle analysis, ensuring the future of CAR-T therapies is both innovative and effective.
—
This restructured approach not only enhances readability but is also designed to optimize search engine discoverability, making it a valuable resource for researchers and professionals in the field of CAR-T therapy development.
